Fundamental Analysis of PRELUDE THERAPEUTICS INC(NASDAQ:PRLD) stock

Fundamental Rating

PRLD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. While PRLD has a great health rating, there are worries on its profitability. PRLD has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PRLD has reported negative net income.

In the past year PRLD has reported a negative cash flow from operations.

In the past 5 years PRLD always reported negative net income.

In the past 5 years PRLD always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -66.69%, PRLD is doing worse than 63.88% of the companies in the same industry.

PRLD has a Return On Equity (-84.07%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-66.69%
ROE	-84.07%
ROIC	N/A

ROA(3y)-44.28%

ROA(5y)-56.84%

ROE(3y)-49.84%

ROE(5y)-67.71%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PRLD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PRLD has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, PRLD has more shares outstanding

There is no outstanding debt for PRLD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

PRLD has an Altman-Z score of -4.54. This is a bad value and indicates that PRLD is not financially healthy and even has some risk of bankruptcy.

PRLD has a worse Altman-Z score (-4.54) than 60.85% of its industry peers.

PRLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-4.54

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 7.04 indicates that PRLD has no problem at all paying its short term obligations.

With a decent Current ratio value of 7.04, PRLD is doing good in the industry, outperforming 67.97% of the companies in the same industry.

A Quick Ratio of 7.04 indicates that PRLD has no problem at all paying its short term obligations.

The Quick ratio of PRLD (7.04) is better than 68.15% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.04
Quick Ratio	7.04

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PRLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.43%, which is quite good.

EPS 1Y (TTM)18.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%4.44%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

PRLD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.45% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y10.81%

EPS Next 2Y11.69%

EPS Next 3Y10.16%

EPS Next 5Y6.45%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PRLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRLD. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y11.69%

EPS Next 3Y10.16%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PRLD does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (12/24/2024, 7:32:46 PM)

After market: 1.1885 0 (-0.13%)

1.19

-0.05 (-4.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-06 2024-11-06/amc

Earnings (Next)02-13 2025-02-13/amc

Inst Owners54.82%

Inst Owner Change5.53%

Ins Owners8.97%

Ins Owner Change5.98%

Market Cap65.50M

Analysts76.36

Price Target5.51 (363.03%)

Short Float %11.14%

Short Ratio7.78

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)2.88%

Min EPS beat(2)-4.88%

Max EPS beat(2)10.65%

EPS beat(4)3

Avg EPS beat(4)7.21%

Min EPS beat(4)-4.88%

Max EPS beat(4)15.1%

EPS beat(8)7

Avg EPS beat(8)11.6%

EPS beat(12)10

Avg EPS beat(12)8.79%

EPS beat(16)11

Avg EPS beat(16)5.24%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-6.9%

PT rev (3m)-6.9%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-10.43%

EPS NY rev (1m)2.47%

EPS NY rev (3m)3.08%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	21.83
P/FCF	N/A
P/OCF	N/A
P/B	0.42
P/tB	0.42
EV/EBITDA	N/A

EPS(TTM)-1.77

EYN/A

EPS(NY)-1.53

Fwd EYN/A

FCF(TTM)-1.95

FCFYN/A

OCF(TTM)-1.92

OCFYN/A

SpS0.05

BVpS2.84

TBVpS2.84

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-66.69%
ROE	-84.07%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-44.28%

ROA(5y)-56.84%

ROE(3y)-49.84%

ROE(5y)-67.71%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	114.39%
Cap/Sales	61.47%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.04
Quick Ratio	7.04
Altman-Z	-4.54

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)260.49%

Cap/Depr(5y)220.31%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)18.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%4.44%

EPS Next Y10.81%

EPS Next 2Y11.69%

EPS Next 3Y10.16%

EPS Next 5Y6.45%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-11.66%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-20.6%

EBIT Next 3Y-14%

EBIT Next 5YN/A

FCF growth 1Y-20.29%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-22.22%

OCF growth 3YN/A

OCF growth 5YN/A

PRELUDE THERAPEUTICS INC (PRLD)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens